Novartis AG Shares Outstanding 2010-2022 | NVS

Novartis AG shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Novartis AG shares outstanding for the quarter ending March 31, 2022 were 2.237B, a 1.24% decline year-over-year.
  • Novartis AG 2021 shares outstanding were 2.26B, a 1.57% decline from 2020.
  • Novartis AG 2020 shares outstanding were 2.296B, a 0.99% decline from 2019.
  • Novartis AG 2019 shares outstanding were 2.319B, a 1.07% decline from 2018.
Novartis AG Annual Shares Outstanding
(Millions of Shares)
2021 2,260
2020 2,296
2019 2,319
2018 2,344
2017 2,371
2016 2,400
2015 2,438
2014 2,426
2013 2,479
2012 2,445
2011 2,413
2010 2,301
2009 2,277
Novartis AG Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 2,237
2021-12-31 2,260
2021-09-30 2,254
2021-06-30 2,258
2021-03-31 2,265
2020-12-31 2,296
2020-09-30 2,302
2020-06-30 2,304
2020-03-31 2,292
2019-12-31 2,319
2019-09-30 2,297
2019-06-30 2,333
2019-03-31 2,339
2018-12-31 2,344
2018-09-30 2,338
2018-06-30 2,346
2018-03-31 2,347
2017-12-31 -1,186
2017-09-30 2,359
2017-06-30 2,373
2017-03-31 2,389
2016-12-31 -1,200
2016-09-30 2,401
2016-06-30 2,401
2016-03-31 2,398
2015-12-31 2,403
2015-09-30 2,438
2015-06-30 2,451
2015-03-31 2,446
2014-12-31 2,426
2014-09-30 2,460
2014-06-30 2,471
2014-03-31 2,479
2013-12-31 2,479
2013-09-30 2,480
2013-06-30 2,490
2013-03-31 2,473
2012-12-31 2,445
2012-09-30 2,445
2012-06-30 2,441
2012-03-31 2,435
2011-12-31 2,413
2011-09-30 2,450
2011-06-30 2,426
2011-03-31 2,305
2010-12-31 2,301
2010-09-30 2,300
2010-06-30 2,297
2010-03-31 2,290
2009-12-31 2,277
2009-09-30 2,285
2009-06-30 2,280
2009-03-31 2,283
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $181.123B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $472.758B 18.18
Eli Lilly (LLY) United States $297.134B 35.06
Pfizer (PFE) United States $281.050B 9.80
AbbVie (ABBV) United States $264.095B 11.58
Merck (MRK) United States $232.650B 13.14
GlaxoSmithKline (GSK) United Kingdom $108.662B 12.69
Novo Nordisk (NVO) Denmark $0.000B 32.27